Markus Warmuth, M.D., is the Chief Executive Officer at Monte Rosa Therapeutics Inc., a position he has held since the company's inception. Dr. Warmuth brings a wealth of experience in the biopharmaceutical industry, with a particular focus on oncology and drug development. Prior to joining Monte Rosa, he served as the Chief Executive Officer of H3 Biomedicine, where he led the company's efforts in developing novel cancer therapies. His leadership at H3 Biomedicine was marked by significant advancements in the company's pipeline and strategic partnerships. Dr. Warmuth's career also includes a notable tenure at Novartis, where he held various leadership positions, including Global Head of Oncology Research. During his time at Novartis, he played a pivotal role in the development and approval of several key oncology drugs, demonstrating his ability to drive innovative research from the lab to the market. His expertise in molecular oncology and targeted therapies has been instrumental in shaping the strategic direction of Monte Rosa Therapeutics. At Monte Rosa Therapeutics, Dr. Warmuth is at the helm of a company dedicated to developing molecular glue degraders, a novel class of drugs designed to target previously undruggable proteins. Under his leadership, Monte Rosa has made significant strides in advancing its pipeline and building a robust platform for drug discovery. Dr. Warmuth's vision for the company is to transform the treatment landscape for patients with serious diseases, leveraging the potential of molecular glue degraders to address unmet medical needs. His strategic leadership and deep understanding of the oncology field continue to drive Monte Rosa's mission forward.